GLP-1 and cardioprotection: from bench to bedside (Q27024984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22419668

27 December 2024

author name string

J. Diez

3

1 reference

Amaia Zudaire

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22419668

27 December 2024

Javier Díez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22419668

27 December 2024

language of work or name

1 reference

1 May 2012

1 reference

14 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22419668

27 December 2024

published in

Cardiovascular Research

1 reference

volume

94

1 reference

issue

2

1 reference

page(s)

316-23

1 reference

Cell death in the pathogenesis of heart disease: mechanisms and significance

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardiac metabolism in myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Myocardial reperfusion: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Lethal myocardial reperfusion injury: a necessary evil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Reperfusion injury induces apoptosis in rabbit cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Gastrointestinal hormones and the regulation of β-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Clinical approaches to preserve beta-cell function in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Understanding the cardiovascular effects of incretin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardiovascular Effects of Glucagonlike peptide–1 Agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVS123

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

21 January 2018

9

1 reference

Intestinal Factors in the Control of Insulin Secretion

27 December 2024

10

1 reference

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

27 December 2024

13

1 reference

The Incretin Axis in Cardiovascular Disease

27 December 2024

23

1 reference

DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion

27 December 2024

33

1 reference

Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men.

27 December 2024

35

1 reference

Apoptosis in myocytes in end-stage heart failure

27 December 2024

36

1 reference

Myocyte death in the failing human heart is gender dependent

27 December 2024

38

1 reference

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

27 December 2024

47

1 reference

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

27 December 2024

50

1 reference

Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway

27 December 2024

51

1 reference

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

27 December 2024

72

1 reference

Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease

27 December 2024

74

1 reference

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

27 December 2024

78

1 reference